Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19
Status:
Completed
Trial end date:
2021-02-15
Target enrollment:
Participant gender:
Summary
This is a two-arm, randomized, open label, two-center, controlled study to evaluate the
safety and efficacy of Viusid plus Asbrip in patients with mild and moderate symptoms of
respiratory illness caused by Coronavirus 2019 infection.